2. Search Result
Search Result
Results for "

PLK1-IN-2

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

4

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114302
    CCB02
    1 Publications Verification

    		 Microtubule/Tubulin Cancer
    CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .
    CCB02
  • HY-126249
    AAPK-25

    		Aurora Kinase Polo-like Kinase (PLK) Apoptosis Cancer
    AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3 Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM .
    AAPK-25
  • HY-139652
    PLK1-IN-2

    		Polo-like Kinase (PLK) Cancer
    PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.
    PLK1-IN-2
  • HY-115589
    YLT-11

    		Polo-like Kinase (PLK) Apoptosis Cancer
    YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .
    YLT-11
  • HY-176734
    CZL-S092

    		Polo-like Kinase (PLK) Cancer
    CZL-S092 is a PLK4 inhibitor with an IC50 value of 0.9 nM and excellent selectivity over other PLK4 family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC50 = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .
    CZL-S092
  • HY-143471
    WNY0824

    PLK1/BRD4-IN-1

    		 Polo-like Kinase (PLK) Epigenetic Reader Domain Apoptosis Androgen Receptor c-Myc Cancer
    WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET protein families, with IC50 values ​​of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide (HY-70002) resistant CRPC xenograft tumor models .
    WNY0824
  • HY-180989
    PROTAC PLK1 Degrader-2

    		PROTACs Polo-like Kinase (PLK) Apoptosis Cancer
    PROTAC PLK1 Degrader-2 (Compound NC1) is a PLK1 PROTAC degrader with an Kd of 6.06 μM. PROTAC PLK1 Degrader-2 significantly inhibits the proliferation of HeLa cells, induces cell cycle arrest and apoptosis. PROTAC PLK1 Degrader-2 exhibits significant anti-tumor activity in a HeLa cell xenograft tumor mouse model. PROTAC PLK1 Degrader-2 can be used for the study of cervical cancer.
    PROTAC PLK1 Degrader-2
  • HY-180991
    Arg12-AHX

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Arg12-AHX is a synthetic E3 ligase-ligand conjugate that can be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). PROTAC PLK1 Degrader-2 is a PLK1 PROTAC degrader with anti-tumor activity .
    Arg12-AHX
  • HY-180990
    POI ligand-3

    		Ligands for Target Protein for PROTAC Polo-like Kinase (PLK) Cancer
    POI ligand-3 (Compound 4j) is a type of peptide-based PLK1 PBD inhibitor. POI ligand-3 can act as a target protein ligand and be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989) .
    POI ligand-3
  • HY-P11631
    Arg12

    		Ligands for E3 Ligase Cancer
    Arg12, a 12-amino acid peptide sequence, is an E3 ubiquitin ligase ligand. Arg12 can be used to synthesize PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). Arg12 can also act as a cell transmembrane peptide (CPP), facilitating the entire molecule to enter the cell .
    Arg12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: